1. In this randomized controlled trial, among patients with chronic spontaneous urticaria who continue to have symptoms while on second-generation...
1. Composite of coronary heart disease death and non-fatal myocardial infarction was less frequent in the CCTA group compared to...
1. CDASI-A score at 12 weeks was significantly lower in dazukibart 600 mg versus placebo, suggesting reduced morbidity. 2. Treatment-related...
1. In this randomized controlled trial, two cycles of neoadjuvant ipilimumab plus nivolumab resulted in longer event-free survival than adjuvant...
1. After almost 10 years of follow-up, adjuvant dabrafenib and trametinib improved relapse-free and metastasis-free survival compared to placebo in...
1. More patients in the delgocitinib cream group reported clear or almost clear skin at week 16 in both the...
1. Across a median follow-up of 48.5 months, usage of tebentafusp for patients with metastatic uveal melanoma was associated with...
1. Significantly more patients in the bimekizumab group than placebo reported improved clinical response at week 16. 2. Treatment-related adverse...
1. Intravenous ertapenem administered for a mean of 13 weeks for patients with hidradenitis suppurativa was associated with improvement in...
1. 18-month recurrence-free survival was significantly greater in the combination therapy group compared to pembrolizumab alone. 2. There were no...
